"What is the upside for Dimerix with its Receptor-HIT platform? Other than DMX-200 we see two main upsides from the platform. Dimerix is currently working on a pipeline of GPCR heteromer-targeting candidates for nonalcoholic steatohepatitis (NASH), diabetic retinopathy, cancer fatigue and multiple sclerosis. In addition to this, it’s not unreasonable to expect Big Pharma to be interested in the platform for its own GPCR drug discovery efforts, particular after two GPCR platform companies, Receptos and Heptares, were acquired in 2015. Two ‘Top 10’ pharma companies, along with Takeda16, Japan’s largest pharmaceutical company, have in the past used Receptor-HIT in paid collaborations with Dimerix scientists." Page 8. Someone asked for more information about the Receptor-HIT platform. Cheers Edit: Takeda is the world's 19 largest pharma company with US$12.8bn in 2016 revenue (source: Pharmaceutical Executive magazine).
Add to My Watchlist
What is My Watchlist?
